Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

被引:25
作者
Heimes, Anne-Sophie [1 ]
Haertner, Franziska [2 ]
Almstedt, Katrin [1 ]
Krajnak, Slavomir [1 ]
Lebrecht, Antje [1 ]
Battista, Marco J. [1 ]
Edlund, Karolina [3 ]
Brenner, Walburgis [1 ]
Hasenburg, Annette [1 ]
Sahin, Ugur [4 ]
Gehrmann, Mathias [5 ]
Hengstler, Jan G. [3 ]
Schmidt, Marcus [1 ]
机构
[1] Univ Med Ctr Mainz, Dept Obstet & Gynecol, D-55131 Mainz, Germany
[2] Univ Med Ctr Mainz, Inst Med Biostat Epidemiol & Informat IMBEI, D-55131 Mainz, Germany
[3] TU Dortmund IfADo, Leibniz Res Ctr Working Environm & Human Factors, D-44139 Dortmund, Germany
[4] Univ Med Ctr Mainz, TRON Translat Oncol, D-55131 Mainz, Germany
[5] Bayer AG, D-42113 Wuppertal, Germany
关键词
interferon; breast cancer; prognosis; molecular subtypes; CHEMOTHERAPY; IMPACT; MARKER;
D O I
10.3390/ijms21197178
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-gamma (IFN-gamma) as a single gene as well as an IFN-gamma signature covering the signaling pathway in 461 breast cancer patients. Prognostic significance of IFN-gamma, as well as the IFN-gamma signature for metastasis-free survival (MFS), were examined using Kaplan-Meier as well as univariate and multivariate Cox regression analyses in the whole cohort and in different molecular subtypes. The independent prognostic significance of IFN-gamma as a single gene was limited to basal-like breast cancer (hazard ratio (HR) 2.779, 95% confidence interval (95% CI) 1.117-6.919, p = 0.028). In contrast, the IFN-gamma-associated gene signature was an independent prognostic factor in the whole cohort (HR 2.287, 95% CI 1.410-3.633, p < 0.001) as well as in the basal-like (HR 3.458, 95% CI 1.154-10.359, p = 0.027) and luminal B (HR 2.690, 95% CI 1.416-5.112, p = 0.003) molecular subtypes. These results underline the subtype-dependent prognostic influence of the immune system in early breast cancer.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 22 条
[1]   IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].
Ayers, Mark ;
Lunceford, Jared ;
Nebozhyn, Michael ;
Murphy, Erin ;
Loboda, Andrey ;
Kaufman, David R. ;
Albright, Andrew ;
Cheng, Jonathan D. ;
Kang, S. Peter ;
Shankaran, Veena ;
Piha-Paul, Sarina A. ;
Yearley, Jennifer ;
Seiwert, Tanguy Y. ;
Ribas, Antoni ;
McClanahan, Terrill K. .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940
[2]   Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer [J].
Callari, Maurizio ;
Musella, Valeria ;
Di Buduo, Eleonora ;
Sensi, Marialuisa ;
Miodini, Patrizia ;
Dugo, Matteo ;
Orlandi, Rosaria ;
Agresti, Roberto ;
Paolini, Biagio ;
Carcangiu, Maria Luisa ;
Cappelletti, Vera ;
Daidone, Maria Grazia .
MOLECULAR ONCOLOGY, 2014, 8 (07) :1278-1289
[3]   Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion [J].
Castro, Flavia ;
Cardoso, Ana Patricia ;
Goncalves, Raquel Madeira ;
Serre, Karine ;
Oliveira, Maria Jose .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[4]   Oncology Meets Immunology: The Cancer-Immunity Cycle [J].
Chen, Daniel S. ;
Mellman, Ira .
IMMUNITY, 2013, 39 (01) :1-10
[5]   Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers [J].
Denkert, Carsten ;
von Minckwitz, Gunter ;
Brase, Jan C. ;
Sinn, Bruno V. ;
Gade, Stephan ;
Kronenwett, Ralf ;
Pfitzner, Berit M. ;
Salat, Christoph ;
Loi, Sherene ;
Schmitt, Wolfgang D. ;
Schem, Christian ;
Fisch, Karin ;
Darb-Esfahani, Silvia ;
Mehta, Keyur ;
Sotiriou, Christos ;
Wienert, Stephan ;
Klare, Peter ;
Andre, Fabrice ;
Klauschen, Frederick ;
Blohmer, Jens-Uwe ;
Krappmann, Kristin ;
Schmidt, Marcus ;
Tesch, Hans ;
Kuemmel, Sherko ;
Sinn, Peter ;
Jackisch, Christian ;
Dietel, Manfred ;
Reimer, Toralf ;
Untch, Michael ;
Loibl, Sibylle .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :983-991
[6]   Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].
Denkert, Carsten ;
Loibl, Sibylle ;
Noske, Aurelia ;
Roller, Marc ;
Mueller, Berit Maria ;
Komor, Martina ;
Budczies, Jan ;
Darb-Esfahani, Silvia ;
Kronenwett, Ralf ;
Hanusch, Claus ;
von Toerne, Christian ;
Weichert, Wilko ;
Engels, Knut ;
Solbach, Christine ;
Schrader, Iris ;
Dietel, Manfred ;
von Minckwitz, Gunter .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113
[7]   Breast Cancer Immunotherapy: Facts and Hopes [J].
Emens, Leisha A. .
CLINICAL CANCER RESEARCH, 2018, 24 (03) :511-520
[8]   A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors [J].
Filipits, Martin ;
Rudas, Margaretha ;
Jakesz, Raimund ;
Dubsky, Peter ;
Fitzal, Florian ;
Singer, Christian F. ;
Dietze, Otto ;
Greil, Richard ;
Jelen, Andrea ;
Sevelda, Paul ;
Freibauer, Christa ;
Mueller, Volkmar ;
Jaenicke, Fritz ;
Schmidt, Marcus ;
Koelbl, Heinz ;
Rody, Achim ;
Kaufmann, Manfred ;
Schroth, Werner ;
Brauch, Hiltrud ;
Schwab, Matthias ;
Fritz, Peter ;
Weber, Karsten E. ;
Feder, Inke S. ;
Hennig, Guido ;
Kronenwett, Ralf ;
Gehrmann, Mathias ;
Gnant, Michael .
CLINICAL CANCER RESEARCH, 2011, 17 (18) :6012-6020
[9]   A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes [J].
Haibe-Kains, Benjamin ;
Desmedt, Christine ;
Loi, Sherene ;
Culhane, Aedin C. ;
Bontempi, Gianluca ;
Quackenbush, John ;
Sotiriou, Christos .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (04) :311-325
[10]   Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer [J].
Heimes, A-S. ;
Madjar, K. ;
Edlund, K. ;
Battista, M. J. ;
Almstedt, K. ;
Elger, T. ;
Krajnak, S. ;
Rahnenfuehrer, J. ;
Brenner, W. ;
Hasenburg, A. ;
Hengstler, J. G. ;
Schmidt, M. .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (02) :293-300